Australia markets open in 3 hours 56 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
43.82+0.21 (+0.48%)
At close: 04:00PM EDT
43.00 -0.82 (-1.87%)
After hours: 04:04PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.55B
Enterprise value 6.59B
Trailing P/E 18.10
Forward P/E 14.53
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.67
Price/book (mrq)31.22
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.26
52-week change 330.96%
S&P500 52-week change 327.04%
52-week high 345.17
52-week low 331.86
50-day moving average 340.27
200-day moving average 338.79

Share statistics

Avg vol (3-month) 31.02M
Avg vol (10-day) 31.15M
Shares outstanding 5127.27M
Implied shares outstanding 6129.37M
Float 8125.87M
% held by insiders 11.11%
% held by institutions 199.12%
Shares short (30 Apr 2024) 48.41M
Short ratio (30 Apr 2024) 49.75
Short % of float (30 Apr 2024) 48.93%
Short % of shares outstanding (30 Apr 2024) 46.61%
Shares short (prior month 28 Mar 2024) 47.89M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 36.94%
Operating margin (ttm)48.78%

Management effectiveness

Return on assets (ttm)13.48%
Return on equity (ttm)261.68%

Income statement

Revenue (ttm)862.99M
Revenue per share (ttm)6.64
Quarterly revenue growth (yoy)20.80%
Gross profit (ttm)N/A
EBITDA 458.42M
Net income avi to common (ttm)318.8M
Diluted EPS (ttm)2.41
Quarterly earnings growth (yoy)93.90%

Balance sheet

Total cash (mrq)463.45M
Total cash per share (mrq)3.64
Total debt (mrq)1.53B
Total debt/equity (mrq)861.96%
Current ratio (mrq)6.64
Book value per share (mrq)1.40

Cash flow statement

Operating cash flow (ttm)431.03M
Levered free cash flow (ttm)320.33M